First Affiliated Hospital of Chengdu Medical College
Age
30–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female, aged between 30-65 years old.
Patients with resist hypertension (office systolic blood pressure ≥140 mmHg, and/or office diastolic blood pressure ≥90 mmHg, and/or 24-h average systolic blood pressure ≥130 mmHg) with rational lifestyle change and triple antihypertensive drugs (irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d) for at least 4 weeks.
Informed consent signed and agreed to participate in this trial.
You may not be if
Secondary hypertension
Adrenergic insufficiency.
adrenocortical insufficiency
Renal failure eGFR\<60 mL/min/1.73 m2
Heart failure with NYHA grade Ⅱ-Ⅳ grade or unstable angina, severe cardiovascular and cerebrovascular stenosis, myocardial infarction, intracranial aneurysm, stroke and other acute cardiovascular events.
Acute infections, tumors and severe arrhythmias, psychiatric disorders, drugs or alcohol addicts.
Liver dysfunction or the following history of liver disease: AST or ALT 3 times higher than the upper limit, liver cirrhosis, history of hepatic encephalopathy, esophageal variceal history or portal shunt history.
Fertile woman without contraceptives.
Coagulation dysfunction.
Pregnant women or lactating women.
Participated in other clinical trials or admitted with other research drugs within 3 months prior to the trial.
Any surgical or medical condition which can significantly alter the absorption, distribution, metabolism, or excretion of any study drug.
Allergy or any contraindications for the study drugs, contrast agents and alcohol.
History of depression, schizophrenia or vascular dementia.
Refused to sign informed consent
Clareo Health | Effectiveness and Safety of BiSAAE for Resistant Hypertension.
